Sterne Agee Sees 16% Upside for Actavis, Initiates Coverage
Shares of Actavis (NYSE: ACT) are up 2.3 percent to $198.42 in Wednesday's trading after Sterne Agee initiated coverage on the stock with a Buy rating and $230 price target.
Analyst Shibani Malhotra sees upside “to the company's pro-revenue and synergy targets, and expects management to continue to implement on its disciplined inorganic growth strategy.”
The analyst is also bullish on the company's growth profile following its recent merger with Forest Laboratories.
Latest Ratings for ACT
Date | Firm | Action | From | To |
---|---|---|---|---|
Oct 2021 | Citigroup | Initiates Coverage On | Buy | |
Oct 2021 | JP Morgan | Initiates Coverage On | Overweight | |
Oct 2021 | Credit Suisse | Initiates Coverage On | Neutral |
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: forest laboratories Shibani Malhotra Sterne AgeeAnalyst Color Initiation Analyst Ratings